AbelZeta
Beyond's analysis on AbelZeta
- — AbelZeta regains global rights to C‑CAR039 (Prizlon‑cel) and secures FDA IND clearance for large B‑cell lymphoma therapy
- — EMA PRIME designation accelerates AbelZeta's lupus therapy C-CAR168 toward faster regulatory approval and market entry
Recent news mentioning AbelZeta
- — AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma
- — AbelZeta Receives FDA Clearance of Registrational Phase II Trial for C-CAR168 in Refractory Lupus Nephritis